Key result
Incretin-based therapies achieve up to ~21% weight loss while reducing cardiometabolic and renal risk.
Why the study?
Although rapid uptake of GLP-1 receptor agonists and tirzepatide has placed nurses at the centre of initiation, titration, education, monitoring, and long-term follow-up, nursing roles are seldom described in the literature.
This narrative review synthesizes landmark trial evidence and safety signals for GLP-1 and dual GIP/GLP-1 receptor agonists into a phase-based nursing care framework to guide safe initiation, titration, monitoring, and long-term patient management.
Answers are grounded in this paper and cite their sources.
May inform nursing surveillance models for incretin therapies; leaves open prospective validation of phase-based protocols.
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide have transformed the treatment of type 2 diabetes and obesity, and their indications now extend to cardiovascular, renal, liver and sleep-related disease. Their rapid uptake has placed nurses at the centre of initiation, titration, education, monitoring and long-term follow-up, yet nursing roles are seldom described in the literature. This narrative review synthesises the published evidence on these medicines from a nursing perspective. The burden of obesity and the evolving concept of clinical obesity are first outlined, followed by the mechanisms of action of incretin-based therapies. The evidence from landmark trials on weight, glycaemic, cardiovascular, kidney, heart failure, sleep apnoea and liver outcomes is then examined. The principal safety concerns are described in an integrated manner, including gastrointestinal effects, dehydration, pancreatobiliary events, peri-procedural aspiration, loss of lean mass, emerging signals and weight regain after discontinuation, together with nursing assessment and actions for each. Finally, a phase-based framework for nursing care, implementation challenges such as equity of access and weight stigma, and priorities for nursing research are considered. By linking pharmacology and trial evidence with practical nursing responsibilities, this review offers a conceptual framework and a practical reference for nurses, educators, managers and policymakers. In sum, the work positions nursing as essential to the safe, equitable and sustained use of incretin-based therapies.
No takes yet. Share an insight, caveat, or question.
Hasan et al. (2026) conducted a review in Obesity, type 2 diabetes, and cardiometabolic disease. GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 receptor agonist (tirzepatide) vs. Placebo or active comparators in reviewed landmark trials was evaluated. GLP-1 receptor agonists and tirzepatide achieve up to 15% to 21% weight loss and reduce cardiometabolic and renal events, requiring structured phase-based nursing care for safe long-term use.
Synapse has enriched 10 related papers. Consider them for comparative context: